ClinicalTrials.gg
CompletedNCT06744205Updated Jun 9, 2026

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

A Phase 1/2 interventional study of Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA) in Influenza and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 24 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,162
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.

Enrollment
25th of 126
1,162 · median 305
Started
2025
with 2 others
Phase 1/2
13 of 139
1 open now
Registered
131st of 139
by date

Among the 139 studies in Influenza, Human by Sanofi, this one is the 25th largest by enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 in phase 1/2, and was the 131st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Influenza, Human by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.

Read the detailed description

Study details include the following:

  • Study Duration: approximately 12 months for each participant
  • Treatment: 1 injection of hexavalent vaccine, trivalent vaccine, or active control
  • Visit frequency: Day (D) 01, D03, D09, D29, and D181; D366 (telephone call)
  • Dose escalation with sequential enrollment of sentinel cohorts followed by parallel enrollment of the main cohort
03

Conditions studied

  • Influenza
  • Healthy Volunteers

Browse trials for

Keywords

  • influenza, flu, vaccine, hexavalent
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant aged 50 years on the day of inclusion
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year, or surgically sterile.

OR

  • Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.

A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours prior to administration of study intervention.

Exclusion criteria

Exclusion Criteria:

Participants are not eligible for the study if any of the following criteria are met:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA vaccine
  • Previous history of myocarditis, pericarditis, and/or myopericarditis
  • Known history of previous episodes of Guillain-Barré syndrome, neuritis (including Bell's palsy), convulsions, encephalitis, transverse myelitis, and vasculitis
  • Participants with an that is consistent with possible myocarditis or pericarditis or, in the opinion of the investigator, demonstrates abnormalities that may affect participant safety or study results
  • Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator's judgment
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination based on Investigator's judgment
  • Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness / infection (according to investigator's judgement) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • Participant who had acute infectious symptoms or a positive SARS-CoV-2 RT-PCR or antigen test in the past 10 days prior to the first visit (V01)
  • Receipt of any vaccine in the 4 weeks preceding study intervention administration or planned receipt of any vaccine in the 4 weeks following study intervention administration
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Previous vaccination against influenza in the previous 6 months with an or marketed vaccine
  • Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration or planned receipt of any mRNA vaccine in the 2 months after study vaccination
  • Participation at the time of study enrollment (or in the 4 weeks preceding study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Self-reported or documented seropositivity for , virus, or virus
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,162 participants (actual)

Study arms

  • Experimental
    Group 1 - Hexavalent (Combination 1)

    Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 1)

    Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)

  • Experimental
    Group 2 - Hexavalent (Combination 2)

    Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 2)

    Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)

  • Experimental
    Group 3 - Hexavalent (Combination 3)

    Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 3)

    Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)

  • Experimental
    Group 4 - Hexavalent (Combination 4)

    Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 4)

    Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)

  • Experimental
    Group 5 - Hexavalent (Combination 5)

    Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 5)

    Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)

  • Experimental
    Group 6 - Hexavalent (Combination 6)

    Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 6)

    Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)

  • Experimental
    Group 7 - TIV mRNA-HA Vaccine 1

    Participants will receive a single dose of TIV mRNA-HA Vaccine 1

    Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1

  • Experimental
    Group 8 - TIV mRNA-NA

    Participants will receive a single dose of TIV mRNA-NA

    Biological: TIV mRNA-neuraminidase (NA)

  • Experimental
    Group 9 - TIV mRNA-HA Vaccine 2

    Participants will receive single dose of TIV mRNA-HA Vaccine 2

    Biological: TIV mRNA-HA Vaccine 2

  • Active comparator
    Group 10 - QIV-SD

    Participants will receive single dose of QIV-SD vaccine (for participants 50 to 64 years of age only)

    Biological: Quadrivalent Influenza Standard Dose Vaccine

  • Active comparator
    Group 11 - QIV-HD

    Participants will receive single dose of QIV-HD vaccine

    Biological: Quadrivalent Influenza Vaccine High Dose

Interventions

  • BiologicalTrivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1

    * Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection

  • BiologicalTIV mRNA-neuraminidase (NA)

    * Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection

  • BiologicalTIV mRNA-HA Vaccine 2

    * Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection

  • BiologicalQuadrivalent Influenza Standard Dose Vaccine

    * Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection

    Also known as: Fluzone Qudrivalent®

  • BiologicalQuadrivalent Influenza Vaccine High Dose

    * Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection

    Also known as: Fluzone High-Dose Quadrivalent®

06

What researchers measure

Primary outcomes

  1. Number of participants with immediate unsolicited systemic adverse events (AEs)

    Unsolicited systemic AEs that occur within 30 minutes after vaccination

    Time frame: Within 30 minutes after injection

  2. Number of participants with solicited injection site reactions

    Solicited injection site reactions pre-listed in the participant diary and in the case report form CRF

    Time frame: Up to 7 days after injection

  3. Number of participants with solicited systemic reactions

    Solicited systemic reactions pre-listed in the participant diary and in the CRF

    Time frame: Up to 7 days after injection

  4. Number of participants with unsolicited AEs

    AEs that do not fulfill the conditions of solicited reactions

    Time frame: Up to 28 days after injection

  5. Number of participants with medically attended adverse events (MAAEs)

    MAAEs reported up to 180 days after injection

    Time frame: Up to 180 days after injection

  6. Number of participants with serious adverse events (SAEs)

    Throughout the study

    Time frame: SAEs throughout the study (Up to approximately 12 months)

  7. Number of participants with adverse events of special interest (AESIs)

    Throughout the study

    Time frame: AESIs throughout the study (Up to approximately 12 months)

  8. Number of participants with out-of-range biological test results

    Out-of-range biological test results (including shift from baseline values)

    Time frame: Up to 8 days after injection

  9. Hemagglutinin inhibition (HAI) titers

    HAI titers at D01 and D29

    Time frame: At Day 1 and Day 29

  10. Individual HAI antibody (Ab) titer ratio D29/D01

    Individual HAI Ab titer ratio D29/D01

    Time frame: At Day 1 and Day 29

  11. Seroconversion (HAI Ab titer)

    Number of participants with HAI Ab titer \< 10 \[1/dil\] at Day 1 and post-injection titer ≥ 40 \[1/dil\] at Day 29, or titer ≥ 10 \[1/dil\] at Day 1 and a ≥ 4-fold increase in titer \[1/dil\] at Day 29

    Time frame: At Day 1 and Day 29

  12. HAI Ab titer ≥ 40 (1/dil)

    HAI Ab titer ≥ 40 (1/dil) at D29

    Time frame: At Day 29

  13. Neuraminidase inhibition (NAI) titers

    NAI titers at D01 and D29

    Time frame: At Day 1 and Day 29

  14. Individual NAI Ab titer ratio D29/D01

    Individual NAI Ab titer ratio D29/D01

    Time frame: At Day 1 and Day 29

  15. Seroconversion (NAI Ab titer)

    Number of participants with NAI Ab titer \< 10 \[1/dil\] at D01 and post-injection titer ≥ 40 \[1/dil\] at D29, or titer ≥ 10 \[1/dil\] at D01 and a ≥ 4-fold increase in titer \[1/dil\] at D29)

    Time frame: At Day 1 and Day 29

  16. NAI Ab titer ≥ 40 (1/dil)

    NAI Ab titer ≥ 40 (1/dil) at D29

    Time frame: At Day 29

  17. 2-fold and 4-fold rise in NAI titers

    2-fold and 4-fold rise in NAI titers from D01 to D29

    Time frame: Day 1 to Day 29

Secondary outcomes

  1. Neutralizing antibodies titers

    Neutralizing antibodies titers at D01 and D29

    Time frame: At Day 1 and Day 29

  2. Individual neutralizing antibodies titer ratio

    Individual neutralizing antibodies titer ratio D29/D01

    Time frame: At Day 1 and Day 29

  3. 2-fold and 4-fold increase in neutralizing titers

    2-fold and 4-fold increase in neutralizing titers D01 through D29

    Time frame: Day 1 to Day 29

07

Study locations

24 sites
  • Accel Research Sites Network - Birmingham- Site Number : 8400008
    Birmingham, Alabama 35216, United States
  • AMR Mobile- Site Number : 8400022
    Mobile, Alabama 36608, United States
  • Alliance for Multispeciality Research - Clinical Research Consortium- Site Number : 8400015
    Tempe, Arizona 85281, United States
  • AMR Miami- Site Number : 8400021
    Coral Gables, Florida 33134, United States
  • Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400003
    DeLand, Florida 32720, United States
  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8400013
    Fort Myers, Florida 33912, United States
  • Accel Research Sites - Maitland- Site Number : 8400007
    Maitland, Florida 32751, United States
  • Innovation Medical Research Center - Palmetto Bay- Site Number : 8400011
    Palmetto Bay, Florida 33157, United States
  • Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400001
    Decatur, Georgia 30030-2627, United States
  • AMR - Chicago- Site Number : 8400012
    Oak Brook, Illinois 60532, United States
  • Alliance for Multispeciality Research - Newton- Site Number : 8400020
    Newton, Kansas 67114, United States
  • Alliance for Multispeciality Research - Wichita East- Site Number : 8400014
    Wichita, Kansas 67207, United States
  • Alliance for Multispeciality Research - Lexington- Site Number : 8400018
    Lexington, Kentucky 40509, United States
  • Boston Clinical Trials- Site Number : 8400009
    Boston, Massachusetts 02131, United States
  • ActivMed Practices & Research- Site Number : 8400005
    Methuen, Massachusetts 03110, United States
  • Quest Research Institute- Site Number : 8400010
    Farmington Hills, Michigan 48334, United States
  • Alliance for Multispeciality Research - Kansas City- Site Number : 8400019
    Kansas City, Missouri 64114, United States
  • AMR Las Vegas - Site Number : 8400016
    Las Vegas, Nevada 89119, United States
  • Coastal Carolina Research Center - North Charleston- Site Number : 8400002
    North Charleston, South Carolina 29405, United States
  • Alliance for Multispeciality Research - Knoxville- Site Number : 8400017
    Knoxville, Tennessee 37920, United States
  • Charlottesville Medical Research- Site Number : 8400004
    Charlottesville, Virginia 22911, United States
  • Investigational Site Number : 0360001
    Botany, New South Wales 2019, Australia
  • Investigational Site Number : 0360003
    Bayswater, Victoria 3153, Australia
  • Investigational Site Number : 0360002
    Melbourne, Victoria 3124, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2026, 16 months.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 20, 2024
StartActual
Jan 6, 2025
Primary completionActual
May 22, 2026
CompletionActual
May 22, 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06744205
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Jan 6, 2025
Primary completion
May 22, 2026
Completion
May 22, 2026
Last update
Jun 9, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion